# Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

> **NCT07551050** · — · RECRUITING · sponsor: **Fudan University** · enrollment: 300 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07551050
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2029-04-15
- **Final completion:** 2029-06-15
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551050, "Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07551050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*